ClinicalTrials.gg
RecruitingNCT05358535PEACUpdated Jan 20, 2026

Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)

A Phase 3 interventional study of Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2) and Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7) in Anesthesia, Propofol Adverse Reaction and Etomidate Adverse Reaction, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by University of Texas Southwestern Medical Center · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States — 13 open to participants now, 18 under way, 2 of them phase 3. Drug-Related Side Effects and Adverse Reactions · United States.

Planned enrollment
39th of 95
200 · median 96
Started
2022
with 5 others
Phase 3
13 of 140
2 open now
Primary completion
2027-01
later than 5 of 17 live
Registered
122nd of 140
by date

Among the 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States, this one is the 39th largest by planned enrollment of the 95 interventional ones that give a count, is one of 6 that started in 2022, is one of 13 in phase 3, reaches primary completion later than 5 of the 17 other live ones, and was the 122nd registered.

Drug-Related Side Effects and Adverse Reactions

449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.

Browse Drug-Related Side Effects and Adverse Reactions studies →

Open to participants now

13 of the 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 38 (68%) set no upper age limit and 15 (27%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 140 studies in Drug-Related Side Effects and Adverse Reactions with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo).

Read the detailed description

Procedural/Surgical anesthesia induction, administration and maintenance with propofol combined with etomidate is commonly used in routine clinical practice in patient with compromised cardiopulmonary status. However, there is no definitive trend or understanding from the literature to discern which ratio of admixture is appropriate for providing stable hemodynamics and minimizing side effects for procedural sedation in gastrointestinal endoscopy procedures. Given the increasing volume for gastrointestinal endoscopy, the increasingly older and greater chronic disease burden of the endoscopic patient population, and the increased utilization of anesthesia for endoscopic procedures this clinical trial aims to provide timely, meaningful and impactful guidance and information for the safe conductance of anesthesia in this patient population.

The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab.

Propofol and etomidate can be mixed together in a syringe or similar container for up to 24 hours without adversely affecting appearance, pH, particle size and distribution, zeta potential, observation under centrifugation and drug content and impurity demonstrating the mixture to be physically and chemically compatible. Propofol and Etomidate are both FDA approved for induction and maintenance of general anesthesia in adult patients. Propofol and Etomidate in a wide ranging ratio of combinations in admixture have been utilized for general anesthesia induction and maintenance both in regular standard of care daily clinical practice and within a profound number of research trials including up to a ratio of 80% etomidate and 20 % propofol by volume. Therefore the clinical practice of etomidate and propofol in admixture for the induction and maintenance of general anesthesia in adult patients is standard of care and well founded in the anesthesiology literature. However, there are several important questions about which potential ratio of both drugs provides the best combination of favorable cardiopulmonary effects while having an acceptably low incidence of adverse effects. Thus, this current proposed trial is intended to answer several important questions on that matter.

This trial also will have actual blinding of both patients and practitioners at time of drug administration. Propofol is a white liquid and etomidate is a clear liquid. Thus, past trials where either pure drug was given in sequence or at the same time by separate syringes could not have had any blinding because of this obvious physical quality of the medications. Therefore, only a trial involving an admixture of varying ratios of both drugs could possibly hope to achieve actual blinding as is required for rigorous analysis of results without introducing the bias that comes from a lack of true blinding of patients and practitioners.

03

Conditions studied

  • Anesthesia
  • Propofol Adverse Reaction
  • Etomidate Adverse Reaction
  • Anesthesia Complication
  • Anesthesia; Adverse Effect
  • Anesthesia; Reaction

Keywords

  • anesthesia
  • anesthesiology
  • adverse drug reaction
  • drug side effect
  • sedation
  • cardiopulmonary
  • hemodynamics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients (age ≥18 years old)
  2. Having endoscopic procedure at CUH with anesthesia
  3. ASA 3 or above
  4. test result available

Exclusion criteria

Exclusion Criteria:

  1. Known allergies or adverse reactions to study drugs or study drug components or preservatives
  2. Patient refusal
  3. Clinician refusal
  4. Documented cognitive impairments precluding subject ability to consent for themselves unless a surrogate documented legally acceptable decision maker consents for patient participation
  5. Prisoner or incarcerated or patients held by law enforcement officials in custody
  6. Pregnancy or patient refusal for pregnancy testing or screening (standard UTSW policy and protocol requires pregnancy testing for appropriate patients prior to anesthesia)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)

    This a prospective double blind randomized controlled clinical trial. The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital endoscopy lab.

    Drug: Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)

  • Experimental
    Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)

    This a prospective double blind randomized controlled clinical trial. The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital endoscopy lab.

    Drug: Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)

Interventions

  • DrugAdmixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2)

    Drug page: PropofolStudies of PropofolPropofol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo). The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab.

    Also known as: propofol, etomidate, P7E2, propofol 75% by volume, etomidate 25% by volume

  • DrugAdmixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)

    Drug page: PropofolStudies of PropofolPropofol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The purpose of this study is to evaluate the hemodynamics and adverse event profile in comparison between two treatment arms, one using an admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7), and one using an admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), for anesthesia during endoscopic procedures at the Clements University Hospital (CUH) endoscopy lab (Endo). The objectives are to compare the treatment arms, P2E7 and P7E2, in a randomized controlled double-blind trial for anesthesia for endoscopic procedures. Comparison between an admixture of Propofol/Etomidate 75%/25% versus 25%/75% being utilized as principal anesthetic for endoscopic procedures at CUH endoscopy lab.

    Also known as: propofol, etomidate, P2E7, propofol 25% by volume, etomidate 75% by volume

06

What researchers measure

Primary outcomes

  1. Time weighted average mean arterial pressure within treatment arm

    Time weighted average mean arterial pressure (every 15 minutes calculate average mean arterial pressure for that interval, then end of case calculate mean of all those means for the entire case)

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  2. Average within treatment arm vasopressor use by number of units

    Vasopressor use by number of units (1 unit of vasopressor being defined as 1 unit vasopressor = 100 mcg phenylephrine = 5 mg ephedrine = 0.5 units vasopressin = 5 mcg norepinephrine)4-9 throughout entire intraoperative period (subjects on vasopressor infusions on arrival for endoscopy will not have those vasopressor units added in UNLESS during case, anesthesia clinicians adjust the infusion based on intraoperative clinical situation as well as all bolus doses and new infusions being added as with all other subjects)

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  3. Average within treatment arm total minutes under 92% oxygen saturation

    Average within treatment arm total minutes under 92% oxygen saturation by pulse oximetry during entire case

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  4. % of cases with any MAP below 50

    % of cases with any MAP below 50

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  5. % of cases with any MAP >60% below patient's immediate preoperative MAP

    % of cases with any MAP \>60% below patient's immediate preoperative MAP

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  6. % of cases with any treatment for Post Operative Nausea and Vomiting

    % of cases with any treatment for Post Operative Nausea and Vomiting

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  7. % of cases with any oxygen saturation event below 85% by pulse oximetry

    % of cases with any oxygen saturation event below 85% by pulse oximetry

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  8. % of cases with any rapid response or code blue event within 24 hours from anesthesia start

    % of cases with any rapid response or code blue event within 24 hours from anesthesia start

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  9. Within treatment arm % of total group with a composite MACE event in the 30 days

    Within treatment arm % of total group with a composite MACE event in the 30 days after starting on day of drug administration

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  10. Within treatment arm % of total group with a classic MACE event in the 30 days

    Within treatment arm % of total group with a classic MACE event in the 30 days after starting on day of drug administration

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  11. Average within treatment arm antiemetic use by number of doses

    Average within treatment arm antiemetic use by number of doses irrespective of antiemetic drug choice

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  12. Average within treatment arm time in minutes after dressing complete to discharge

    Average within treatment arm time in minutes after dressing complete to discharge to next phase of care or to home from immediate recovery phase of care

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

Secondary outcomes

  1. Within each treatment arm, average of anesthesia clinicians' assessment of quality

    Within each treatment arm, average of anesthesia clinicians' assessment of quality of anesthesia during case: Poor, Below Average, Average, Above Average, Excellent (0,1,2,3,4) from all anesthesia staff then average for each treatment arm

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  2. Within each treatment arm, average of endoscopists' assessment of quality

    Within each treatment arm, average of endoscopists' assessment of quality of anesthesia during case: Poor, Below Average, Average, Above Average, Excellent (0,1,2,3,4) from all endoscopy staff then average for each treatment arm

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  3. Within each treatment arm, average of patients' assessment of quality

    Within each treatment arm, average of patients' assessment of quality of anesthesia during case: Poor, Below Average, Average, Above Average, Excellent (0,1,2,3,4) from all patients then average for each treatment arm

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  4. Within each treatment arm, number of events of any use of 2 or more

    Within each treatment arm, number of events of any use of 2 or more different (beyond study admixtures) sedative or anesthetic adjunct medications

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  5. Within each treatment arm, number of events of any use of two or more

    Within each treatment arm, number of events of any use of two or more types of antiemetic drugs

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  6. Average time in immediate recovery area before discharge to next phase of care

    Average time in immediate recovery area before discharge to next phase of care or to home

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  7. Average time from dressing complete to modified Aldrete score >8

    Average time from dressing complete to modified Aldrete score \>8

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  8. Within each treatment arm number of composite MACE events in the 30 days

    Within each treatment arm number of composite MACE events in the 30 days after starting on day of drug administration

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  9. Within each treatment arm number of classic MACE events in the 30 days

    Within each treatment arm number of classic MACE events in the 30 days after starting on day of drug administration

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  10. Average within treatment arm total dose (mL) of admixture administered

    Average within treatment arm total dose (mL) of admixture administered during entire case divided by average time from induction to dressing complete (minutes)

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  11. Average within treatment arm total dose (mg) of etomidate during entire case

    Average within treatment arm total dose (mg) of etomidate during entire case divided by average time from induction to dressing complete (minutes)

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  12. Average within treatment arm total dose (mg) of propofol during entire case

    Average within treatment arm total dose (mg) of propofol during entire case divided by average time from induction to dressing complete (minutes)

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  13. Average within treatment arm total dose of adjunct sedatives

    Average within treatment arm total dose of fentanyl, sufentanil, midazolam, diphenhydramine, ketamine, morphine, hydromorphone, dexmedetomidine, undiluted propofol, undiluted etomidate (either in mcg or mg as appropriate for each drug) divided by average time from induction to dressing complete (minutes)

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  14. Within each treatment arm, number of events of any episode of vomiting

    Within each treatment arm, number of events of any episode of vomiting

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  15. Within each treatment arm, number of events of any complaint of nausea

    Within each treatment arm, number of events of any complaint of nausea

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  16. Within each treatment arm, number of events of any syncopal event

    Within each treatment arm, number of events of any syncopal event

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  17. Within each treatment arm, number of events of any use of one type of antiemetic drug

    Within each treatment arm, number of events of any use of one type of antiemetic drug

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  18. Within each treatment arm, number of events of any unanticipated admission

    Within each treatment arm, number of events of any unanticipated admission, or transfer to higher level of care in the 24 hours after starting on day of drug administration

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  19. Within each treatment arm, number of events of any airway adjunct usage

    Within each treatment arm, number of events of any airway adjunct usage (oral airway, nasal airway, need for intermittent mask ventilation)

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

  20. Within each treatment arm, number of events of any use of any additional sedatives

    Within each treatment arm, number of events of any use of any additional sedative or anesthetic adjunct medication (beyond study admixtures) during case (fentanyl, sufentanil, midazolam, diphenhydramine, ketamine, morphine, hydromorphone, dexmedetomidine, undiluted propofol, undiluted etomidate)

    Time frame: Throughout entire study estimated to take 6 to 12 months to complete

07

Study locations

1 of 1 sites recruiting
  • Clements University Hospital
    Dallas, Texas 75390, United States
    Recruiting
    • Joseph M Hendrix, MD · Contact8172667987
08

References and documents

Publications

  • Chen L, Liang X, Tan X, Wen H, Jiang J, Li Y. Safety and efficacy of combined use of propofol and etomidate for sedation during gastroscopy: Systematic review and meta-analysis. Medicine (Baltimore). 2019 May;98(20):e15712. doi: 10.1097/MD.0000000000015712. PubMed 31096522 ↗
  • Yoon SW, Choi GJ, Lee OH, Yoon IJ, Kang H, Baek CW, Jung YH, Woo YC. Comparison of propofol monotherapy and propofol combination therapy for sedation during gastrointestinal endoscopy: A systematic review and meta-analysis. Dig Endosc. 2018 Sep;30(5):580-591. doi: 10.1111/den.13050. Epub 2018 Apr 17. PubMed 29526045 ↗
  • Hao L, Hu X, Zhu B, Li W, Huang X, Kang F. Clinical observation of the combined use of propofol and etomidate in painless gastroscopy. Medicine (Baltimore). 2020 Nov 6;99(45):e23061. doi: 10.1097/MD.0000000000023061. PubMed 33157963 ↗
  • Goradia S, Sardaneh AA, Narayan SW, Penm J, Patanwala AE. Vasopressor dose equivalence: A scoping review and suggested formula. J Crit Care. 2021 Feb;61:233-240. doi: 10.1016/j.jcrc.2020.11.002. Epub 2020 Nov 14. PubMed 33220576 ↗
  • Saravanan S, Kocarev M, Wilson RC, Watkins E, Columb MO, Lyons G. Equivalent dose of ephedrine and phenylephrine in the prevention of post-spinal hypotension in Caesarean section. Br J Anaesth. 2006 Jan;96(1):95-9. doi: 10.1093/bja/aei265. Epub 2005 Nov 25. PubMed 16311286 ↗
  • French WB, Rothstein WB, Scott MJ. Time to Use Peripheral Norepinephrine in the Operating Room. Anesth Analg. 2021 Jul 1;133(1):284-288. doi: 10.1213/ANE.0000000000005558. No abstract available. PubMed 33886514 ↗
  • Mohta M, Dubey M, Malhotra RK, Tyagi A. Comparison of the potency of phenylephrine and norepinephrine bolus doses used to treat post-spinal hypotension during elective caesarean section. Int J Obstet Anesth. 2019 May;38:25-31. doi: 10.1016/j.ijoa.2018.12.002. Epub 2018 Dec 13. PubMed 30685301 ↗

Individual participant data

Plan to share: Yes — PHI (name, date of birth, Medical Record number, phone number, email account, admission date) Demographics (Age, height, weight, BMI) Medical history Medication list Intraoperative data collection Time weighted average mean arterial pressure (every 15 minutes calculate average mean arterial pressure for that interval, then end of case calculate mean of all those means for the entire case) Area Under the Threshold for mean arterial pressure (both predefined threshold of 65 mm Hg and for 40% below patient's immediate preoperative MAP) Vasopressor use by number of units (1 unit of vasopressor being defined as 1 unit vasopressor = 100 mcg phenylephrine = 5 mg ephedrine = 0.5 units vasopressin = 5 mcg norepinephrine)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: At conclusion of all data analysis and available permanently

Access criteria: Only study personnel

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Jan 2027, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2022
First posted
May 3, 2022
StartActual
Sep 19, 2022
Primary completionEst.
Jan 2027
CompletionEst.
Mar 2027
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05358535
Responsible party
Christopher Choi (Assistant Professor of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center) — Principal investigator
First posted
May 3, 2022
Start date
Sep 19, 2022
Primary completion
Jan 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jan 20, 2026

Study contacts

Christopher Choi
Contact
christopher.choi@utsouthwestern.edu
2146486400
Kapil Anand
Contact
kapil.anand@utsouthwestern.edu
2146486400
Kapil Anand
study director · University of Texas

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propofol

Start the discussion